Publications

Jongo S, Ackermann E, Nyaulingo G, Mbaraka H, Reus E, Cicconi S, Saxena M, Kassim K, Tumbo A, Rashid M.A, Robinson S, Louis M, Satam V, Rocha Fbds, Scandale I, Assmus F, Keiser J, Specht S. Pharmacokinetics, safety, and tolerability of an oxfendazole tablet formulation: a phase 1, randomized, placebo-controlled trial in healthy African volunteers. Antimicrob Agents Chemother. 2026(in press):e0131525. DOI: 10.1128/aac.01315-25

Kahatano A.E, Mpina M, Vanobberghen F, Hassan O, Urasa N, Sasamalo I, Mswata S, Paris D, Gajewski S, Saxena M, Fürle K, Kiehl V, Böhnlein E, Aschenbrenner A, Lanzer M, Thomson-Luque R, Olotu A, Daubenberger C. Full-length merozoite surface protein 1 formulated with GLA-SE adjuvant in malaria pre-exposed adults: a randomised, controlled, double-blind, parallel-group, single-centre Phase Ib trial. EClinicalMedicine. 2025;89:103585. DOI: 10.1016/j.eclinm.2025.103585